Gilead Sciences has drawn attention to itself with a possible coronavirus treatment -- but that isn’t the main reason to invest in the company.
Stitch Fix is getting to know its customers even better -- and showing it can offer more than a fix.
It was a non-event for the shares and further developments may result in the same lack of excitement.
Target’s disappointing holiday sales have weighed on its stock performance -- but, overall, the company’s growth story remains encouraging.
With a new drug on the market and another being reviewed by the FDA, Seattle Genetics’ revenue potential is climbing.
Share volatility and rumors of a Victoria’s Secret sale stir up uncertainty for investors.
Sanofi is betting on its eczema drug to redefine the company and boost revenue -- even with competition on the horizon.
Macy’s and Sephora are opening stores in neighborhoods -- right where the customer shops the most.
Boston Scientific’s recent earnings report was mixed, but FDA clearance of a potentially blockbuster device could drive future revenue -- and stock performance.
Biogen’s victory in a patent case involving its blockbuster multiple sclerosis drug is positive, but other uncertainties are waiting in the wings.
How many times have you asked yourself how Amazon.com shares can possibly move higher? Steady revenue and profit growth, as well as diversification, may be why it’s rarely too late to buy into the Amazon story.
Amgen’s pipeline and an oncology collaboration in China are reasons to believe the recent revenue slowdown may be transient.
Investors worried about a slowdown in revenue as biosimilars are rivals to older drugs.
The FDA’s approval sets the company off on the right path as it advances in the treatment of food allergies.
Illumina’s share of the sequencing market, new collaboration agreement with Roche, and growth in the clinical oncology business position it for long-term revenue growth.
Amazon Web Service growth has slowed but the cloud business still is part of the forces lifting Amazon shares skyward.
Luxury-goods makers are losing out on sales in one of their big markets, but that doesn’t mean it’s time to sell their shares.
Beyond Meat has tempted investors with great gains, but an unfolding lawsuit could make the stock one they no longer want on the menu.
Here are three biotech companies with solid, revenue-driving products to add to portfolios while the price is right.
Analysts are upgrading L Brands, but declining revenue at the Victoria’s Secret chain means recovery still remains far off.